Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
Public ClinicalTrials.gov record NCT00499707. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Fixed Dose Rosiglitazone/Metformin Combination Therapy Compared to Both Rosiglitazone and Metformin Monotherapies in Drug Naive Type 2 Diabetes Mellitus Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.
Study identification
- NCT ID
- NCT00499707
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 453 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 8, 2003 (Type not available)
- Primary completion
- Dec 1, 2004 (Actual)
- Completion
- Dec 16, 2004 (Actual)
- Last update posted
- Mar 21, 2018
2003 – 2004
United States locations
- U.S. sites
- 48
- U.S. states
- 18
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Chandler | Arizona | 85224 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Phoenix | Arizona | 85050 | — |
| GSK Investigational Site | Tucson | Arizona | 85745 | — |
| GSK Investigational Site | Encinitas | California | 92024 | — |
| GSK Investigational Site | Fullerton | California | 92835 | — |
| GSK Investigational Site | Los Banos | California | 93635 | — |
| GSK Investigational Site | Mission Viejo | California | 92691 | — |
| GSK Investigational Site | Jacksonville | Florida | 32204 | — |
| GSK Investigational Site | Melbourne | Florida | 32901 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | Orlando | Florida | 32806 | — |
| GSK Investigational Site | Saint Cloud | Florida | 34769 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Fayetteville | Georgia | 30214 | — |
| GSK Investigational Site | Woodstock | Georgia | 30189 | — |
| GSK Investigational Site | Chicago | Illinois | 60607 | — |
| GSK Investigational Site | Evansville | Indiana | 47713 | — |
| GSK Investigational Site | Newburgh | Indiana | 47630 | — |
| GSK Investigational Site | Slidell | Louisiana | 70461 | — |
| GSK Investigational Site | Jackson | Mississippi | 39202 | — |
| GSK Investigational Site | Chesterfield | Missouri | 63017 | — |
| GSK Investigational Site | Kansas City | Missouri | 64111 | — |
| GSK Investigational Site | St Louis | Missouri | 63376 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89103 | — |
| GSK Investigational Site | Kingston | New York | 12401 | — |
| GSK Investigational Site | New York | New York | 10024 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28210 | — |
| GSK Investigational Site | Mogadore | Ohio | 44260 | — |
| GSK Investigational Site | Downingtown | Pennsylvania | 19335 | — |
| GSK Investigational Site | Warminster | Pennsylvania | 18974 | — |
| GSK Investigational Site | West Chester | Pennsylvania | 19382 | — |
| GSK Investigational Site | Bristol | Tennessee | 37620 | — |
| GSK Investigational Site | Johnson City | Tennessee | 37601 | — |
| GSK Investigational Site | Arlington | Texas | 76017 | — |
| GSK Investigational Site | Beaumont | Texas | 77701 | — |
| GSK Investigational Site | Bryan | Texas | 77802 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Midland | Texas | 79705 | — |
| GSK Investigational Site | San Antonio | Texas | 78221 | — |
| GSK Investigational Site | San Antonio | Texas | 78237 | — |
| GSK Investigational Site | Seattle | Washington | 98108 | — |
| GSK Investigational Site | Spokane | Washington | 99207 | — |
| GSK Investigational Site | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00499707, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2018 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00499707 live on ClinicalTrials.gov.